Investigation of the Effect of the Atherogenic Index on the Therapeutic Response to Tadalafil in Patients With Vascular Erectile Dysfunction

This study aims to investigate the relationship between the atherogenic index of plasma (AIP) and the therapeutic response to daily tadalafil 5 mg treatment in patients diagnosed with vascular erectile dysfunction (VED). AIP is considered a marker of atherogenic dyslipidemia and subclinical atherosclerosis and is calculated using the formula log10 (triglycerides/HDL-C). Since vascular abnormalities play a major role in the pathophysiology of erectile dysfunction, AIP may reflect underlying vascular risk and potentially predict treatment outcomes. In this prospective observational study, patients with vascular erectile dysfunction will receive tadalafil 5 mg once daily for one month, and treatment response will be evaluated by comparing clinical parameters before and after therapy.

NCT Number	NCT07479901
Lead Sponsor	Taksim Egitim ve Arastirma Hastanesi
Conditions	Erectile Dysfunction Vascular Erectile Dysfunction Atherogenic Dyslipidemia
Enrollment	132 participants
Start Date	2025-10-12
Primary Completion	2026-03-21 (estimated)
Study Completion	2027-04-20 (estimated)
Updated on ClinicalTrials.gov	2026-06-08